Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 7/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13057758 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4EHPGDCRHBPCRHR2 | |
| SCHEMBL18339257 | 0.72 | MAPK1 (0.52) | ALDH1A1KDM4EHPGDCRHBPCRHR2 | |
| SCHEMBL14321805 | 0.69 | MAPK1 (0.47) | ALDH1A1KDM4EHPGDCRHBPCRHR2 | |
| SCHEMBL5391946 | 0.69 | MAPK1 (0.55) | ALDH1A1KDM4EHPGDCRHBPCRHR2 | |
| SCHEMBL5297079 | 0.69 | MAPK1 (0.55) | ALDH1A1KDM4EHPGDCRHBPCRHR2 | |
| SCHEMBL1300746 | 0.69 | MAPK1 (0.55) | ALDH1A1KDM4EHPGDCRHBPCRHR2 | |
| SCHEMBL11074361 | 0.69 | MAPK1 (0.55) | ALDH1A1KDM4EHPGDCRHBPCRHR2 | |
| SCHEMBL228374 | 0.69 | MAPK1 (0.55) | ALDH1A1KDM4EHPGDCRHBPCRHR2 | |
| SCHEMBL6267714 | 0.66 | CXCR3 (0.52) | KDM4EHTTMAPK1TSHRCXCR3 | |
| Alpha-Pinene SCHEMBL338721 | 0.61 | MAPK1 (0.92) | ALDH1A1KDM4EHTTMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298569-A1 | USE OF CYCLOVINYL PHOSPHINE/COPPER COMPLEXES AS ARYLATION CATALYSTS | CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298569-A1 | USE OF CYCLOVINYL PHOSPHINE/COPPER COMPLEXES AS ARYLATION CATALYSTS | CPNE4, CBR3, DDT | ALDH1A1 2819/4885KDM4E 2772/4885HPGD 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.